Joint statement on TNM 8th Edition head and neck
by the British Society of Head and Neck Imaging (BSHNI), the British Association of Head and Neck Oncologists (BAHNO), the British Association of Oral and Maxillofacial Surgeons (BAOMS), the British Association of Otorhinolaryngologists and Head and Neck Surgeons (ENT UK), the National Cancer Research Institute (NCRI) head neck group, the Royal College of Pathologists (RCPath), and the Royal College of Radiologists (RCR)
- We support the adoption of TNM v8 for the description of anatomical extent of disease in head and neck cancer (including thyroid cancer), starting from the 1st of June 2018.
- We strongly recommend that no change in treatment occurs, and that treatment decision making continues to be undertaken according to existing treatment guidelines. For example, T2 p16+ oropharyngeal cancer with unilateral involved nodes (T2N2b TNMv7, T2N1 v8) still requires chemoradiotherapy if treated by primary non-surgical treatment, even though prognostically it has moved from Stage IVa disease in TNM v7 to Stage I disease in TNM v8.
- We recommend that MDTs record the final staging of each case in both TNM v7 and TNM v8 formats until the end of 2018.
- For oropharyngeal cancers, we acknowledge that the final MDT staging will require the result of the p16 immunohistochemistry to be known. Until the p16 immunohistochemistry result is available when including a staging in the report, the reports of the provisional TNM v8 staging for oropharyngeal cancers should specify p16 negative staging pending outcome of p16 result. The text of reports should continue to include all features that are important for treatment planning and staging as a p16 positive tumour e.g. presence and location of nodes with extracapsular spread.
- We recommend that for ongoing clinical trials, eligibility criteria should be explained in a written format, e.g. patients with extracapsular spread, patients with multiple unilateral or bilateral nodes, and that the eligibility criteria should specify both a TNM v7 and a TNM v8 staging to avoid confusion.
- We strongly recommend that ongoing trials collect both TNM v7 and TNM v8 tumour and nodal staging data, and that the independent data monitoring committees of ongoing trials continue to prospectively monitor randomisation by TNM v8 as well as TNM v7 to ensure that treatment arms are well balanced. This will enable trials to report results by both TNM v7 and TNM v8 staging.
- BAHNO, BAOMS, BSHNI, ENT UK, RCPath, RCR, and NCRI Head and Neck Group will engage in joint education activities, including lectures and online presentation, to disseminate the above and to help implement the TNM v8 during transition.
BAHNO AGM 2018
This will be held at 10.15 on 25th May 2018 at the RCP.
Please click AGM Agenda 2018 for the agenda.
Minutes of the last AGM AGM_Minutes_2017 nr
Clinical Excellence Awards
Information on the Advisory Committee on Clinical Excellence Awards (ACCEA) 2018 round is now available on the ACCEA website. We want to draw your attention to this and ensure you have the information required as the deadlines are very tight.
All applications must be with the ACCEA by Thursday 12 April 2018. The responsibility for the online submission of the application to ACCEA rests firmly with the applicant. For more information on how to apply, visit the ACCEA website.
If you would like to be considered for BAHNO, email your completed ACCEA application forms to secretariat@BAHNO.org by 10am on Monday 5th March 2018.
Please note that you must supply newly completed forms for renewal applications by the dates above. At this stage, we are accepting the 2017 ACCEA application forms as changes to the 2018 form are expected to be minimal. Please specifically outline your contribution to BAHNO and Head & Neck Oncology. We encourage you to apply to both your Specialist Association and the Royal Colleges for a place on their ranking list. If you wish for both organisations to consider your application, you must send your CVQ to both organisations as we do not exchange CVQ information.
BAHNO’s interim position regarding TNM 8
As you are aware, the AJCC TNM 8 for head and neck tumours has come into force from the beginning of Jan 2018. However, the new staging system has not yet been accepted by some clinicians and pathologists as suitable for both prognosis and the management of malignancies at all head and neck sites.
BAHNO Council feels that further discussion is required to determine how the transition from TNM 7 to TNM 8 can be safely managed.
To that end, a meeting is planned between BAHNO Council, the NCRI ‘s head and neck group and the Royal College of Pathologists to agree a common position and recommendation. The meeting will be held on 5th Feb 2018. Thereafter, we plan to seek the endorsement of other related associations. We therefore hope to be able to publish a consensus statement by beginning of March 2018.
Till then, it is recommended that AJCC/UICC TNM 7 data should continue to be collected, and continue to be used for treatment decision making.
Data using the AJCC TNM 8 system should also be collected, in addition to AJCC/UICC TNM7, but TNM8 should NOT currently be used to determine treatment decisions.
Chair: Sat Parmar
Members: Prasad Kothari, Andrew Robson, Jeremy McMahan
International Collaboration Committee
Chair: Cyrus Kerawala
Members: Navin Mani, Omar Ahmed, Rahul Jayaram
Public Engagement Committee
Chair: Anastasios Kanatas
Members: Helen Cocks, Bhavin Visavadia, S Ramkumar
Online Media Committee
Chair: Jason Fleming
Members: Syed Ali Khurram
Chair: Vinidh Paleri
Membership Engagement Committee
Chair: Ceri Hughes
The Laryngectomee Guide
The Guide provides practical information on medical; dental and psychological issues; side effects of radiation and chemotherapy; methods of speaking; airway, stoma, and voice prosthesis care; eating and swallowing; medical, dental and psychological issues; respiration; anesthesia; and travelling. The Guide was endorsed by the American Academy of Otolaryngology Head and Neck Surgery and is widely used in North America by laryngectomees and speech and language pathologists.
The American Academy of Otolaryngology Head and Neck Surgery has made the Guide available at their website: http://www.entnet.org/content/laryngectomee-guide
World Congress on Thyroid Cancer, Boston
You can now access video coverage of a large group of the most significant premier WCTC presentations by using this link: http://thyroidworldcongress.com/videos-2017
The WCTC3.5 will be held in Rome, Italy in June 2019. The planning is currently in process and the venue, date and program will be announced as planning advances.
WCTC4 will be held again in Boston July 29 to August 1, 2021 and we hope to welcome you to both of these outstanding programs. More information will be available on the main website.
Call for nominations for Council
Nominations are sought for the following posts on Council:
Hon Administrative Secretary Hon Admin 2018
Four-year tenure; post currently held by Nicolas Roland (who is not eligible for re-election)
Hon Treasurer Hon Treasurer 2018
Four-year tenure; post currently held by Cyrus Kerawala (who is eligible for re-election)
One OMFS Representative Specialty reps
Four-year tenure; post currently held by Sat Parmar (who is eligible for re-election)
One Oncology Representative Specialty reps
Four-year tenure; post currently held by Bernadette Foran (who is eligible for re-election)
Please click here to see the BAHNO Strategy
INVITATION TO JOIN AN INTERNATIONAL QUALITATIVE STUDY ON FAST-TRACK CANCER REFERRAL
We are undertaking a study comparing fast-track head and neck cancer referral in England and The Netherlands. This study is being undertaken jointly between the University of Oxford and The Free University of Amsterdam.
Several studies have identified a higher 1-year survival rate for head and neck cancer in Holland than in England, despite conditional 5-year survivals being similar and we are investigating whether differences in the referral systems may be contributing.
We are undertaking this study qualitatively and we are seeking English head and neck surgeons (not trainees) with either an ENT or maxillofacial background to volunteer to be interviewed for the English part of this study.
The study will involve a single qualitative interview at a place convenient to the participant (we’ll come to you!) lasting approximately 45 minutes. Interviews will be conducted by Steve Langton, Consultant Maxillofacial Surgeon.
If you would like to take part, or would like further information please contact Steve at firstname.lastname@example.org or text/mobile 07831622877
BASO-ACS GRANTS AND FELLOWSHIPS
BASO Raven Travelling Fellowship
Applications are invited for The BASO Raven Travelling Fellowship 2017. The award is for a maximum of £2,000 and may be awarded to one or several individuals. The scholarship is open to UK-residents trainees or recently appointed consultants. Applicants need not be members of BASO_ACS or BASO Trainees Group (although this is desirable) but applications must relate to the aims and objectives of the Association.
Closing date: Friday 22nd September 2017
Please visit baso.org.uk for details
BASO-ACS (NIHR) PROJECT GRANT 2017
A grant awarded to assist surgeons to undertake research projects related to surgical or surgically linked cancer care.
Applications are sought for discrete projects such as projects seeking funding for the initial development of clinical trials, studies aimed at initial data collection to inform the design of a future trail or systematic reviews. Three awards up to total value of £6,000 will be made.
Closing date: Monday 2nd October 2017
Please visit www.baso.org.uk for details
- COP newsletter Issue 2 September 2015 FINAL
NEWSLETTER WINTER 2016 newsletter-winter-2016-2017-final
NEWSLETTER AUTUMN 2015 NEWSLETTER WINTER 2015
NEWSLETTER AUTUMN 2014 Newsletter 2014
NEWSLETTER AUTUMN 2013 Newsletter 2013
IFNOS FELLOWSHIP PROGRAMME
The Global On Line Fellowship (GOLF)
Download brochure: 2015 Brochure
Consultation on H&N Cancer in Fanconi’s
Jeremy McMahon is coordinating a consultation exercise to produce a consensus document on H&N Cancer in patients with Fanconi’s Anaemia. Click here for the draft. Please contact Jeremy at: Jeremy.McMahon@ggc.scot.nhs.uk with your comments.
QUALITY OF LIFE ASSESSMENT
BAHNO is actively involved in promoting the assessment of outcomes in head and neck cancer. The measurement of health related quality of life is an important part of this process and, following a presentation at the 2001 Annual Meeting, BAHNO Council is recommending the adoption of the University of Washington questionnaire as part of the minimum dataset. Further information and details of useful websites are given in a summary prepared by Simon Rogers .
Improving Outcomes in Head and Neck Cancers
The consultation version of this document has been produced by the National Institute for Clinical Excellence and is now available. It can be downloaded from the NICE website where further information about the project can be found.